Vanderbilt University
vanderbilt.eduMatched: Vanderbilt University Medical Center · Vanderbilt University
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,339
Active
258
Phase 3
47
Total enrollment
5,991,891
Pipeline matrix
Showing 40 of 102 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Botulinum Toxin Type A | — | — | — | — | 3 | ||
| ValACYclovir 1000 MG | — | — | — | — | — | 1 | |
| Shingrix | — | — | — | — | — | 1 | |
| Botulinum Toxin Type A Injection [Botox] | — | — | — | — | — | 1 | |
| Pimavanserin | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 300 mcg | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 600 mcg | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 900 mcg | — | — | — | — | — | 1 | |
| Buccal Placebo | — | — | — | — | — | 1 | |
| Oral Placebo | — | — | — | — | — | 1 | |
| Oral immediate-release oxycodone 10mg | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 450mcg | — | — | — | — | — | 1 | |
| GlyNAC | — | — | — | — | — | 1 | |
| Lidocaine HCl 0.8% in D5W | — | — | — | — | — | 1 | |
| Vericiguat | — | — | — | — | — | 1 | |
| Hydroxyurea | — | — | 5 | ||||
| Sodium Chloride 0.9% | — | — | — | — | 2 | ||
| Icatibant | — | — | — | 5 | |||
| Dexmedetomidine | — | — | 5 | ||||
| Polyethylene Glycol 3350 | — | — | — | — | — | 1 | |
| Deutetrabenazine | — | — | — | — | — | 1 | |
| Nitric Oxide | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Artificial Tears Methylcellulose | — | — | — | — | — | 1 | |
| Midazolam | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | 3 | ||
| Saline | 11 | ||||||
| 2-Hydroxybenzylamine | — | — | — | — | — | 3 | |
| Theophylline | — | — | — | — | — | 3 | |
| Transdermal Nicotine patch | — | — | — | — | — | 3 | |
| High Dose Quadrivalent Inactivated Influenza Vaccine | — | — | — | — | — | 2 | |
| Standard Dose Quadrivalent Inactivated Influenza Vaccine | — | — | — | — | — | 2 | |
| Moxonidine | — | — | — | — | 2 | ||
| Placebos | — | — | — | 5 | |||
| Amlodipine | — | — | — | — | 2 | ||
| Galantamine | — | — | — | — | 3 | ||
| Empagliflozin 25 MG | — | — | — | — | — | 2 | |
| CO2 gel mask | — | — | — | — | — | 1 | |
| RhPDGF-BB | — | — | — | — | — | 1 | |
| Protocolized diuretic therapy | — | — | — | — | — | 1 |
62 more active programs hidden
Next readouts
- 2025-10-30
- 2025-12-31
- 2025-12-31
- 2026-03-31
- 2026-04-17
- 2026-06
- 2026-06
- 2026-06
- 2026-06
- 2026-06-30
Top conditions
- Obesity56
- Hypertension34
- Depression26
- Delirium22
- Autism Spectrum Disorder20
- Critical Illness18
- Type 2 Diabetes17
- Postural Tachycardia Syndrome17
Frequently asked questions about Vanderbilt University
- How many clinical trials does Vanderbilt University have on ClinicalTrials.gov?
- Vanderbilt University is listed as the lead sponsor on 1,339 clinical trials in ClinicalTrials.gov, 258 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Vanderbilt University's trials are in Phase 3?
- 47 of Vanderbilt University's trials are in Phase 3, spread across 102 active drug programs.
- What therapeutic areas does Vanderbilt University focus on?
- Vanderbilt University's most-studied conditions on ClinicalTrials.gov are Obesity, Hypertension, Depression, Delirium, Autism Spectrum Disorder.
- When are Vanderbilt University's next clinical trial readouts?
- Vanderbilt University has 10 upcoming primary-completion readouts tracked here; the soonest is “Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)”, expected around 2025-10-30.